Scalability, yield and quality of recombinant AAVs are a significant issue during manufacture. Here the authors describe a self-inhibiting helper adenovirus strategy that improves outcomes compared to helper-free approaches.
- Weiheng Su
- Maria I. Patrício
- Ryan Cawood